- Home
- OPHC vs OTLK Comparison
OPHC vs OTLK Comparison
Compare OPHC & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- OTLK
- Stock Information
- Founded
- OPHC 2000
- OTLK 2010
- Country
- OPHC United States
- OTLK United States
- Employees
- OPHC N/A
- OTLK N/A
- Industry
- OPHC Major Banks
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPHC Finance
- OTLK Health Care
- Exchange
- OPHC Nasdaq
- OTLK Nasdaq
- Market Cap
- OPHC 51.8M
- OTLK 42.8M
- IPO Year
- OPHC N/A
- OTLK 2016
- Fundamental
- Price
- OPHC $4.14
- OTLK $1.22
- Analyst Decision
- OPHC
- OTLK Buy
- Analyst Count
- OPHC 0
- OTLK 5
- Target Price
- OPHC N/A
- OTLK $5.25
- AVG Volume (30 Days)
- OPHC 12.9K
- OTLK 2.7M
- Earning Date
- OPHC 11-07-2025
- OTLK 08-14-2025
- Dividend Yield
- OPHC N/A
- OTLK N/A
- EPS Growth
- OPHC 6.01
- OTLK N/A
- EPS
- OPHC 1.28
- OTLK N/A
- Revenue
- OPHC $41,269,000.00
- OTLK $1,505,322.00
- Revenue This Year
- OPHC N/A
- OTLK N/A
- Revenue Next Year
- OPHC N/A
- OTLK $343.94
- P/E Ratio
- OPHC $3.25
- OTLK N/A
- Revenue Growth
- OPHC 36.79
- OTLK N/A
- 52 Week Low
- OPHC $3.53
- OTLK $0.79
- 52 Week High
- OPHC $5.90
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- OPHC 45.49
- OTLK 51.07
- Support Level
- OPHC $4.10
- OTLK $1.04
- Resistance Level
- OPHC $4.26
- OTLK $1.13
- Average True Range (ATR)
- OPHC 0.08
- OTLK 0.07
- MACD
- OPHC 0.01
- OTLK 0.06
- Stochastic Oscillator
- OPHC 36.33
- OTLK 76.05
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.